Frederick Oncology & Hematology Associates Joins Maryland Oncology Hematology and The US Oncology Network
Affiliation enhances care at both practices, expanding Maryland Oncology Hematology’s services into the Baltimore–Washington Metropolitan Area
Columbia, Md. (November 3, 2017) — Maryland Oncology Hematology (MOH), a premier provider of community-based advanced cancer care services throughout the Maryland/Washington D.C. region and an affiliate of The US Oncology Network (The Network), announced that Frederick Oncology & Hematology Associates (FOHA) has joined its practice. With the addition of FOHA, Maryland Oncology Hematology broadens its service area into the Baltimore–Washington Metropolitan Area, while FOHA gains access to the many resources available from MOH and The US Oncology Network. The US Oncology Network is supported by McKesson Specialty Health, an industry leader in solutions that empower the community patient care delivery system to advance the science, technology and quality of care.
“Frederick Oncology & Hematology Associates is highly regarded in the medical community as a cancer practice that provides the very latest cutting-edge treatments to its patients, coupled with personalized, compassionate care,” said Edward J. Lee, M.D., president of MOH. “The addition of this highly-skilled group of like-minded physicians and their staff brings additional expertise and new ideas to our practice. It will also allow us to continue our mission of providing high-quality, community-based care by adding two convenient locations to serve patients.”
Frederick Oncology & Hematology Associates’ four medical oncologists, one internal medicine physician and two advanced practice providers will join MOH’s 29 physicians to offer advanced treatment options and high-quality integrated cancer care in convenient community settings across Maryland and the surrounding D.C. area. The affiliation will allow MOH to expand its comprehensive cancer care services by adding treatment locations in Frederick and Mt. Airy, Maryland.
“By uniting with Maryland Oncology Hematology, we enhance our ability to provide high-quality advanced care by accessing additional leading-edge technologies and therapies, including groundbreaking clinical trials that our patients can participate in close to home,” said Kanan H. Hudhud, M.D., medical oncologist with FOHA. “We also look forward to utilizing some of the innovative business support tools available from The Network to increase efficiencies. We are excited to join MOH and The Network, as we believe this collaboration positions us well to thrive in today’s evolving environment, both clinically and operationally.”
Maryland Oncology Hematology is affiliated with The US Oncology Network, one of the nation’s largest networks of integrated community-based oncology practices. By joining MOH, physicians from Frederick Oncology & Hematology Associates gain access to the extensive resources of The Network, such as the award winning iKnowMedSM electronic health record and the innovative Lynx Mobile® drug inventory management system, as well as Value Pathways powered by NCCN,®evidence-based treatment guidelines developed by The Network physicians working with the National Comprehensive Cancer Network. Physicians from FOHA can also participate in novel clinical trials through US Oncology Research, the renowned research arm of The Network that has played a role in approximately 70 FDA-approved cancer therapies. Additionally, FOHA physicians can interact with a large physician community through participation in committees, workshops, conferences and by accessing The Oncology Portal, where 1,400 physicians from across The Network can share best practices and collaborate on complex cases in a secure online forum.
“Since the majority of cancer care is delivered in community-based settings, it is extremely important to cancer patients and their families that practices like Frederick Oncology & Hematology Associates remain strong and viable at a time when so many independent cancer centers are closing or consolidating,” said Ella Friedman, senior vice president of Operations for The US Oncology Network. “Uniting with The Network enables practices to tap into our vast operational and clinical solutions that drive quality care while enabling providers to meet the challenges today’s value-based environment presents. We welcome Frederick Oncology & Hematology Associates into The Network, and we look forward to collaborating with these highly-skilled cancer specialists to achieve our common goals of improving access, quality and cost of cancer care.”
About Maryland Oncology Hematology
Maryland Oncology Hematology (MOH) provides comprehensive, compassionate care to people challenged by cancer and blood disorders in Maryland and the surrounding D.C. area. Founded in 1986, MOH has evolved into a world-class treatment center offering a fully integrated approach to cancer treatment. Its dedicated physicians, nurses and staff guide patients and their families through treatment options, tailoring services to each patient’s unique, individual needs. State-of-the-art infusion centers offer a full range of chemotherapy services, laboratory testing, clinical trials and support services provided by people who have an unwavering commitment to achieving the best possible result. Maryland Oncology Hematology’s 34 physicians practice in 11 locations, providing comprehensive cancer care throughout Maryland to the communities of Columbia, Silver Spring, Wheaton, Brandywine, Laurel, Clinton, Lanham, Rockville, Bethesda, Mt. Airy and Frederick.
Maryland Oncology Hematology is an affiliate of The US Oncology Network. This collaboration unites MOH with more than 1,400 independent physicians dedicated to delivering value-based, integrated care for patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The US Oncology Network is supported by McKesson Specialty Health, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. Maryland Oncology Hematology also participates in clinical trials through US Oncology Research, which has played a role in approximately 70 FDA-approved cancer therapies, about one-third of all cancer therapies approved by the FDA to date. For more information, visit www.usoncology.com.
The US Oncology Network